Prevalence of paste despite's ruminants in goats and their blood pictures

Abstract

A comparative study on the prevalence and blood pictures in Peste des petits ruminants (PPR)-affected goats registered to veterinary hospitals in Bangladesh was conducted at one filed veterinary hospital named Parbatipur Upazila Veterinary Hospital located in Parbatipur, Dinajpur and one referral veterinary hospital named SAQ Teaching Veterinary Hospital located at the Chittagong Veterinary and Animal Sciences University (CVASU). The study was conducted in June-August 2010 at the field veterinary hospital and in December 2010-January 2011 at the referral veterinary hospital. During these two phases of the study prevalence and blood pictures of PPR-affected goats were studied. Detail history, physical examination, clinical examination, hematological examination, postmortem examination, vaccination program and response to treatment were assessed. The results revealed that, the overall prevalence of PPR in the goats registered to veterinary hospitals is 40.2; younger goats of <12 months of age were more susceptible (51.4%) to PPR than the older ones (21.2%). The prevalence of PPR was higher (49.5%) in the unvaccinated compared with the vaccinated (16.7%) goats. The disease was proportionately higher in Black Bengal breed (44.4%) compared with Jamunapari (32.6%). PPR was more prevalent in July-August than in January. The prevalence of PPR in the hospital-registered goats was higher (46.8%) in the field veterinary hospital (Parbatipur Upazila Veterinary Hospital) than the referral hospital at CVASU (21.2%), indicating that PPR is distributed country-wide. The MEAN ± SEM Hb (8.8±1.34g %), PCV (18±3.02%),ESR (0±0 hour), Lymphocyte (60.5±1.84%), Nutrophil (30±1.47%), Monocyte (5.75±1.25%), Eosinophils (3.75±0.75%), Basophiles (0±0%), TEC (9.19±1.59×106/μl) and TLC (9.98±1.50×10³/μl), respectively. Response to treatment with parenteral (I/M) use of oxytetracycline was comparatively higher than that of achieved with the parenteral use of sulphonamide 66.6%) or oral/gut active use of sulphonamide (50.0%).